Update on perioperative systemic therapy for urothelial carcinoma

Research output: Contribution to journalArticlepeer-review

Abstract

Level 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint inhibitors are encouraging, but long-term follow-up is required. Randomized trials have failed to accrue a sufficient number of patients and have not demonstrated a survival benefit with adjuvant chemotherapy in MIUBC, but for those with high-risk features at surgery, adjuvant cisplatin-based therapy is appropriate. In upper tract urothelial carcinoma, several retrospective trials and one recent phase 2 prospective trial support the use of NAC, and a randomized trial with adjuvant chemotherapy demonstrated improved disease- and metastasis-free survival and a trend toward improved overall survival.

Original languageEnglish
Pages (from-to)176-183
Number of pages8
JournalClinical Advances in Hematology and Oncology
Volume17
Issue number3
StatePublished - Mar 2019

Keywords

  • Adjuvant
  • Chemotherapy
  • Immunotherapy
  • Neoadjuvant
  • Urothelial cancer

Fingerprint

Dive into the research topics of 'Update on perioperative systemic therapy for urothelial carcinoma'. Together they form a unique fingerprint.

Cite this